FDA Approval for Lurbinectedin
Lurbinectedin (brand name Zepzelca) is FDA-approved as monotherapy for metastatic small cell lung cancer (SCLC) in adults with disease progression on or after platinum-based chemotherapy.[1]
Clinical Evidence in Small Cell Lung Cancer
In the phase 2 CORSAIR trial and phase 3 ATLANTIS study, lurbinectedin showed antitumor activity primarily in relapsed SCLC, with overall response rates of 35-46% in sensitive relapse cases and 22-27% in resistant relapse. Median progression-free survival reached 5.1 months in monotherapy settings.[2][3]
Activity in Other Cancer Types
Lurbinectedin has demonstrated responses in preclinical and early-phase trials across additional solid tumors, though not FDA-approved for these:
- Lung cancers beyond SCLC: Partial responses in non-small cell lung cancer (NSCLC), including squamous and non-squamous subtypes (response rates ~20% in phase 2).[4]
- Mesothelioma: Objective responses in 10-15% of malignant pleural mesothelioma patients in basket trials.[5]
- Ovarian cancer: Activity in platinum-resistant cases, with response rates around 25% when combined with other agents.[6]
- Other sarcomas and neuroendocrine tumors: Single-agent responses reported in uterine leiomyosarcoma, endometrial stromal sarcoma, and small cell cancers of the ovary or prostate.[7]
| Cancer Type | Response Rate (Key Trials) | Notes |
|-------------|----------------------------|-------|
| Small Cell Lung Cancer | 35-46% (sensitive relapse) | FDA-approved setting |
| NSCLC | ~20% | Phase 2 data |
| Mesothelioma | 10-15% | Basket trials |
| Platinum-Resistant Ovarian | ~25% (combo) | Early phase |
Ongoing Trials and Combinations
Over 50 active trials explore lurbinectedin in combinations (e.g., with irinotecan, atezolizumab) for SCLC, NSCLC, head/neck squamous cell carcinoma, triple-negative breast cancer, and soft tissue sarcomas. Phase 3 trials target extensive-stage SCLC frontline and relapsed NSCLC.[8]
Limitations and Patient Selection
Responses are strongest in SCLC with limited prior lines of therapy. No approvals exist for extrapulmonary small cell carcinomas despite some activity. Tumor transcription factor expression (e.g., high INSM1) may predict better outcomes.[9]
Sources
[1]: FDA.gov - Zepzelca Approval Summary (https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-lurbinectedin-metastatic-small-cell-lung-cancer)
[2]: Trigo et al., Lancet Oncol 2020 (CORSAIR trial)
[3]: Liu et al., J Clin Oncol 2024 (ATLANTIS trial)
[4]: Farago et al., Clin Cancer Res 2019
[5]: [ClinicalTrials.gov summaries]
[6]: Phase 2 ovarian data, Ann Oncol
[7]: Paz-Ares et al., ESMO 2018
[8]: ClinicalTrials.gov search for lurbinectedin
[9]: Biomarker analyses from phase 2/3 trials